Compare Toast Inc. Class A Common Stock (TOST) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toast Inc. Class A Common Stock vs Viatris Inc — how do they compare? Toast Inc. Class A Common Stock trades at $29.99 (market cap $17.25B), while Viatris Inc trades at $17.62 (market cap $20.05B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.75% dividend while Toast Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Toast Inc. Class A Common Stock for 0 Days and Viatris Inc for 57 Days on average.
| TOST | VTRS | |
|---|---|---|
Market Cap | $17.25B | $20.05B |
Volume | 10,274,535 | 8,682,135 |
Sector | Technology | Health |
52-Week High | $39.02 | $18.27 |
52-Week Low | $22.33 | $9.98 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $15.50B | $32.16B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Toast (TOST) trades at $30.89, down 1.37% on the day, with neutral technical indicators showing support at $30 and resistance at $32. The company demonstrates strong fundamental performance with 23% revenue growth in Q2 2026 to $1.91B and expanding profit margins, though valuation metrics remain elevated with a P/E of 39.1. Recent expansion into convenience stores with Toast Fuel and AI-driven product enhancements signal continued growth initiatives.
The outlook remains positive with 61.8% analyst buy ratings and a $38.22 consensus price target representing 24% upside potential. Key risks include execution challenges in new market segments and competitive pressures in the restaurant technology space, while strong earnings beats and institutional support provide confidence in the growth trajectory.
Viatris (VTRS) trades at $17.25, down 1.65% on the day, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported a net loss of $3.51 billion for 2025, though recent quarters have consistently beaten EPS estimates. Revenue remains stable around $14.3 billion, with a dividend of $0.12 declared for September 2026. The balance sheet shows a debt-to-asset ratio of 38.74% for 2025, with positive operating cash flow of $2.32 billion.
The outlook is mixed: analyst consensus is a Buy with a $22.17 price target, indicating 28% upside, supported by strong cash generation and pipeline progress. However, persistent net losses, high P/E ratio of 236.2, and competitive pressures in the generics market pose significant risks. Investor sentiment is cautiously optimistic, driven by earnings beats and strategic approvals like WAKIX in Japan.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Toast Inc. Class A Common Stock
Toast Inc. provides a cloud-based technology platform for the restaurant industry, combining point-of-sale hardware and software with payment processing, online ordering, payroll, and supplier management tools. The platform serves restaurants ranging from single locations to multi-unit groups across US.
Read more on TOST →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
